Shire PLC (LON:SHP)‘s stock had its “buy” rating reaffirmed by equities researchers at Deutsche Bank AG in a research report issued on Wednesday. They currently have a GBX 6,200 ($76.73) price target on the biopharmaceutical company’s stock. Deutsche Bank AG’s target price suggests a potential upside of 18.77% from the stock’s current price.

Several other research firms have also recently weighed in on SHP. Liberum Capital reissued a “buy” rating and set a GBX 5,500 ($68.07) price objective on shares of Shire PLC in a research report on Friday, July 29th. Goldman Sachs Group Inc. reissued a “conviction-buy” rating and set a GBX 6,300 ($77.97) price objective on shares of Shire PLC in a research report on Thursday, September 29th. BNP Paribas reissued an “outperform” rating and set a GBX 5,700 ($70.54) price objective on shares of Shire PLC in a research report on Monday, August 1st. Berenberg Bank reaffirmed a “buy” rating and issued a GBX 5,800 ($71.78) price target on shares of Shire PLC in a report on Wednesday, July 6th. Finally, Shore Capital reaffirmed a “buy” rating on shares of Shire PLC in a report on Friday, July 22nd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and sixteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of GBX 5,841.33 ($72.29).

Analyst Recommendations for Shire PLC (LON:SHP)

Shares of Shire PLC (LON:SHP) opened at 5170.00 on Wednesday. The firm’s 50-day moving average price is GBX 5,001.78 and its 200-day moving average price is GBX 4,587.48. Shire PLC has a 52 week low of GBX 2,707.19 and a 52 week high of GBX 5,377.00. The firm’s market cap is GBX 35.30 billion.

The firm also recently disclosed a dividend, which was paid on Friday, October 7th. Investors of record on Thursday, September 8th were paid a dividend of GBX 3.51 ($0.04) per share. This represents a yield of 0.07%. The ex-dividend date was Thursday, September 8th.

In other Shire PLC news, insider Dominic Blakemore acquired 133 shares of the company’s stock in a transaction that occurred on Friday, September 30th. The shares were acquired at an average price of GBX 5,010 ($62.00) per share, with a total value of £6,663.30 ($8,246.66).

About Shire PLC

Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.